Get the Stockscreener App
16.27
1.94%
0.33
Arcus Biosciences Inc stock is traded at $16.27, with a volume of 186.28K.
It is up +1.94% in the last 24 hours and up +4.84% over the past month.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
See More
Previous Close:
$15.94
Open:
$15.9
24h Volume:
186.28K
Relative Volume:
0.28
Market Cap:
$1.46B
Revenue:
$247.00M
Net Income/Loss:
$-249.00M
P/E Ratio:
-4.1086
EPS:
-3.96
Net Cash Flow:
$-267.00M
1W Performance:
+2.91%
1M Performance:
+4.84%
6M Performance:
+2.59%
1Y Performance:
+1.12%
1-Day Range:
$15.63
$16.47
1-Week Range:
$15.13
$16.47
52-Week Range:
$13.52
$20.31
Arcus Biosciences Inc Stock (RCUS) Company Profile
Name
Arcus Biosciences Inc
Sector
Industry
Phone
(510) 694-6200
Address
3928 POINT EDEN WAY, HAYWARD, CA
Compare RCUS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
16.25 | 1.46B | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.76 | 119.71B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.60 | 82.77B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
618.67 | 37.02B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.09 | 32.26B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.50 | 28.24B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-24 | Initiated | H.C. Wainwright | Neutral |
| Oct-08-24 | Initiated | Wells Fargo | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Nov-23-20 | Initiated | Evercore ISI | Outperform |
| Apr-03-20 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Sep-27-19 | Initiated | Mizuho | Buy |
| May-24-19 | Resumed | Citigroup | Buy |
| Oct-09-18 | Initiated | Wedbush | Outperform |
| Apr-09-18 | Initiated | Citigroup | Buy |
| Apr-09-18 | Initiated | Goldman | Neutral |
| Apr-09-18 | Initiated | Leerink Partners | Outperform |
View All
Arcus Biosciences Inc Stock (RCUS) Latest News
Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend - Benzinga
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Suvretta Capital Management LLC Trims Position in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
Algert Global LLC Has $1.73 Million Position in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
Arcus up 4% following Merck Welireg kidney cancer data - MSN
When (RCUS) Moves Investors should Listen - Stock Traders Daily
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Has $14.24 Million Stake in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
RCUS (Arcus Biosciences) Cash-to-Debt : 18.78 (As of Sep. 2024) - GuruFocus.com
Arcus Biosciences, Inc.'s (NYSE:RCUS) Price Is Right But Growth Is Lacking - Simply Wall St
Arcus Biosciences, Inc. (NYSE:RCUS) Q3 2024 Earnings Call Transcript - MSN
Arcus Biosciences to Present at Evercore and Citi Healthcare Conferences in December | RCUS Stock News - StockTitan
Arcus Biosciences' SWOT analysis: biotech stock faces pivotal data releases - Investing.com
Arcus Biosciences' SWOT analysis: biotech stock faces pivotal data releases By Investing.com - Investing.com Australia
FMR LLC Bolsters Stake in Arcus Biosciences Inc - GuruFocus.com
Arcus Biosciences Awards Key Equity Grants to New Hires at $17.85 Per Share | RCUS Stock News - StockTitan
GSA Capital Partners LLP Raises Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
FY2024 Earnings Forecast for RCUS Issued By HC Wainwright - MarketBeat
Analysts Have Made A Financial Statement On Arcus Biosciences, Inc.'s (NYSE:RCUS) Third-Quarter Report - Yahoo Finance
Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Tops Revenue Estimates - MSN
Arcus Biosciences (NYSE:RCUS) Posts Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Arcus Biosciences Inc (RCUS) Q3 2024 Earnings Call Highlights: S - GuruFocus.com
Arcus Biosciences Inc (RCUS) Q3 2024 Earnings Call Highlights: Strong Cash Position and ... - Yahoo Finance
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Rating of “Buy” from Analysts - Defense World
Analysts Set Arcus Biosciences, Inc. (NYSE:RCUS) Price Target at $33.67 - MarketBeat
Arcus Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Arcus Biosciences Surges: 34% Cancer Trial Success, AstraZeneca Deal Boosts Q3 | RCUS Stock News - StockTitan
Arcus Biosciences (NYSE:RCUS) Receives "Neutral" Rating from HC Wainwright - MarketBeat
Expert Outlook: Arcus Biosciences Through The Eyes Of 8 Analysts - Benzinga
Arcus Biosciences Reports Q3 2024 Results - TipRanks
Arcus says Gilead-partnered cancer therapy cut death risk by 36% - Seeking Alpha
Arcus reports improved survival with cancer drug combo - Investing.com
Arcus Biosciences (RCUS) Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10 - StreetInsider.com
Arcus Bio's Cancer Drug Combo Cuts Death Risk by 36%, Doubles Survival Time in Lung Cancer Trial | RCUS Stock News - StockTitan
What To Expect From Arcus Biosciences Inc (RCUS) Q3 2024 Earnings - GuruFocus.com
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Sold by Allspring Global Investments Holdings LLC - Defense World
(RCUS) Pivots Trading Plans and Risk Controls - Stock Traders Daily
This Arcus Biosciences Insider Reduced Their Stake By 27% - Simply Wall St
Analysts Estimate Arcus Biosciences, Inc. (RCUS) to Report a Decline in Earnings: What to Look Out for - MSN
Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting - StockTitan
Arcus Biosciences (RCUS) Set to Announce Quarterly Earnings on Wednesday - MarketBeat
Arcus Biosciences: Advancing On Several Fronts (NYSE:RCUS) - Seeking Alpha
Arcus Biosciences (NYSE:RCUS) Trading Down 5.3%Should You Sell? - MarketBeat
Arcus Biosciences (NYSE:RCUS) Price Target Raised to $29.00 at Barclays - MarketBeat
Arcus Biosciences' SWOT analysis: stock outlook hinges on clinical trials - Investing.com India
Arcus Begins Differentiating Its HIF-2a inhibitor Versus Merck’s Welireg - Scrip
Arcus Biosciences Announces New Employment Inducement Grants - StockTitan
Health Care Down Amid Mixed Drug Developments -- Health Care Roundup - Marketscreener.com
Citi raises Arcus Biosciences target to $46, maintains buy By Investing.com - Investing.com Canada
Arcus Biosciences (RCUS) PT Raised to $46 at Citi - StreetInsider.com
Neutral stance on Arcus Biosciences maintained by BofA - Investing.com Canada
BofA Securities Reiterates Neutral Rating on Arcus Biosciences (RCUS) - StreetInsider.com
Arcus Biosciences Inc Stock (RCUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.04%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):